explore -WSS

explore

author：fashion 2025-10-01 06:01:48 - browse：8885

Sarepta - Cambridge -AP — Kristoffer Tripplaar/Sipa via AP

To hear Sarepta CEO Doug Ingram tell it, the results Monday afternoon from a large trial of its gene therapy for Duchenne muscular dystrophy marked a clear medical breakthrough. “A massive win,” he told investors, that could lead to its approval for all patients with the fatal muscle-wasting disease regardless of age.

And yet the rest of the Duchenne community was more cautious in its enthusiasm. The study — the most rigorous test to date of a technology 30 years in the making — had technically failed, as so many had before it.

“It’s extremely frustrating,” said John Brandsema, a pediatric neurologist at Children’s Hospital of Philadelphia who worked on the study. “When you spend decades trying to bring therapies into the clinic for something so severe and just keep missing over and over again.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： New air purifier tech could be key to improving indoor air quality
Next article： YouTube cracks down on misinformation on cancer treatment

explore

WSS

Treatments for cramps don't cut it. Why aren't there better options?

Abridge raises $150m as clinical notes automation market heats up

Novo Nordisk touts Wegovy study, but still struggling with supply

Judge sides with young activists in first

Hospitals are dialing back on venture capital investing

Yogurt drink instead of a colonoscopy? CRISPR bacteria are tested

entertainment

explore

focus

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Weight loss drugs aren’t covered by Obamacare. That may change

After affirmative action ruling, medical educators look to 'holistic review'

Reporting on presidential health from Reagan to Trump and Biden

BioMarin wins approval for gene therapy to treat hemophilia A

Maui wildfire now ranks as the fifth

Virginia high school admissions case could be legal follow

Surprise medical billing ban raises prices elsewhere

What does generative AI mean for health care? We asked experts

Surge in Apellis stock fueled by confidence in safety of its eye drug

knowledge

A new drug could help frostbite victims avoid its ravages

Hospitals are piloting generative AI tools as regulators play catch

Megan Rapinoe shares emotional post following US Women's World Cup exit

Medicare Advantage enrollment hits roughly 33.4 million

In 'major milestone,' FDA approves first cell therapy for solid tumors

In 'major milestone,' FDA approves first cell therapy for solid tumors

leisure time

explore

entertainment

focus